Principal Financial Group Inc Alkermes Plc. Transaction History

Principal Financial Group Inc

$172 Billion
Q3 2024

A detailed history of Principal Financial Group Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Principal Financial Group Inc holds 877,943 shares of ALKS stock, worth $25.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

877,943

Previous 947,316 7.32%

Holding current value

$25.9 Million

Previous $22.8 Million 7.63%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$23.01 - $28.55 $1.6 Million - $1.98 Million	-69,373 Reduced 7.32%	877,943 $24.6 Million
Q2 2024 Jul 29, 2024	SELL	$23.21 - $27.24 $724,964 - $850,841	-31,235 Reduced 3.19%	947,316 $22.8 Million
Q1 2024 Apr 29, 2024	BUY	$26.4 - $32.56 $1.03 Million - $1.27 Million	39,009 Added 4.15%	978,551 $26.5 Million
Q4 2023 Feb 07, 2024	BUY	$23.37 - $28.68 $20.2 Million - $24.8 Million	864,389 Added 1150.17%	939,542 $26.1 Million
Q3 2023 Nov 02, 2023	BUY	$27.17 - $31.97 $317,834 - $373,985	11,698 Added 18.44%	75,153 $2.11 Million
Q2 2023 Aug 07, 2023	SELL	$28.34 - $33.63 $209,375 - $248,458	-7,388 Reduced 10.43%	63,455 $1.99 Million
Q1 2023 May 09, 2023	SELL	$25.31 - $29.02 $227,815 - $261,209	-9,001 Reduced 11.27%	70,843 $2 Million
Q4 2022 Feb 09, 2023	BUY	$21.94 - $26.24 $120,648 - $144,293	5,499 Added 7.4%	79,844 $2.09 Million
Q3 2022 Nov 09, 2022	SELL	$22.0 - $31.87 $1.57 Million - $2.28 Million	-71,401 Reduced 48.99%	74,345 $1.66 Million
Q2 2022 Aug 10, 2022	SELL	$26.4 - $30.54 $1.5 Million - $1.73 Million	-56,759 Reduced 28.03%	145,746 $4.34 Million
Q1 2022 May 09, 2022	SELL	$23.07 - $27.99 $1.73 Million - $2.1 Million	-75,152 Reduced 27.07%	202,505 $5.33 Million
Q4 2021 Feb 09, 2022	BUY	$21.47 - $32.08 $52,859 - $78,980	2,462 Added 0.89%	277,657 $6.46 Million
Q3 2021 Nov 09, 2021	BUY	$23.37 - $32.13 $191,961 - $263,915	8,214 Added 3.08%	275,195 $8.49 Million
Q2 2021 Aug 10, 2021	BUY	$18.78 - $25.15 $124,567 - $166,819	6,633 Added 2.55%	266,981 $6.55 Million
Q1 2021 May 10, 2021	BUY	$18.21 - $23.2 $633,471 - $807,058	34,787 Added 15.42%	260,348 $4.86 Million
Q4 2020 Feb 08, 2021	SELL	$15.39 - $22.1 $846,757 - $1.22 Million	-55,020 Reduced 19.61%	225,561 $4.5 Million
Q3 2020 Nov 06, 2020	BUY	$16.16 - $20.66 $1.74 Million - $2.22 Million	107,627 Added 62.23%	280,581 $4.65 Million
Q2 2020 Aug 05, 2020	BUY	$13.31 - $19.41 $1.77 Million - $2.58 Million	132,733 Added 330.01%	172,954 $3.36 Million
Q1 2020 May 12, 2020	BUY	$13.06 - $21.24 $54,734 - $89,016	4,191 Added 11.63%	40,221 $580,000
Q4 2019 Feb 05, 2020	SELL	$17.29 - $21.74 $19,278 - $24,240	-1,115 Reduced 3.0%	36,030 $735,000
Q3 2019 Nov 13, 2019	BUY	$19.51 - $24.28 $936 - $1,165	48 Added 0.13%	37,145 $725,000
Q2 2019 Aug 12, 2019	SELL	$21.47 - $37.33 $103,700 - $180,303	-4,830 Reduced 11.52%	37,097 $836,000
Q1 2019 May 10, 2019	BUY	$28.4 - $36.49 $84,745 - $108,886	2,984 Added 7.66%	41,927 $1.53 Million
Q4 2018 Feb 14, 2019	SELL	$27.94 - $44.61 $189,768 - $302,991	-6,792 Reduced 14.85%	38,943 $1.15 Million
Q3 2018 Nov 14, 2018	BUY	$38.6 - $46.12 $69,480 - $83,016	1,800 Added 4.1%	45,735 $1.94 Million
Q2 2018 Aug 13, 2018	SELL	$40.56 - $51.36 $152,830 - $193,524	-3,768 Reduced 7.9%	43,935 $0
Q1 2018 May 14, 2018	BUY	$53.61 - $67.26 $121,373 - $152,276	2,264 Added 4.98%	47,703 $2.76 Million
Q4 2017 Feb 13, 2018	BUY	$47.69 - $55.39 $1.16 Million - $1.35 Million	24,413 Added 116.11%	45,439 $2.49 Million
Q3 2017 Nov 02, 2017	BUY	$49.16 - $54.45 $1.03 Million - $1.14 Million	21,026	21,026 $1.07 Million

Others Institutions Holding ALKS

# of Institutions

363

Shares Held

182M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.84B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Alkermes Plc. Transaction History